BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 13, 2011
View Archived Issues
Myrexis divulges new inhibitors of TBK1 and/or IKK-epsilon
Read More
Expression of SCCA serpin B3 as a marker of breast cancer progression
Read More
Snapshots: Promising preclinical data on ImmunoGen's anticancer agents IMGN-853 and IMGN-529
Read More
Asthma drug zileuton inhibits amyloid plaque formation in model of Alzheimer's disease
Read More
New antiviral agent OBR-5-340 is active against coxsackievirus B3 and rhinovirus 5
Read More
First-in-human data reported on FAB Pharma's antibacterial agent MUT-056399
Read More
Atox Bio completes phase I trial of immunomodulator AB-103
Read More
FDA accepts EffRx's NDA for EX-101 for osteoporosis
Read More
Novel MEK/ERK inhibitors disclosed by Bayer Schering Pharma
Read More
Novartis patents new sodium/glucose cotransporter inhibitors
Read More
FDA accepts Insys Therapeutics' NDA for fentanyl sublingual spray
Read More
Can-Fite reports interim analysis data from phase I/II CF-102 trial in liver cancer
Read More
Fibrotech Therapeutics presents novel antifibrotic compounds
Read More
Phase IIa trial of CYT-107 plus capecitabine in metastatic breast cancer begins in France
Read More
New fatty acid synthase inhibitors prepared
Read More
Merck KGaA designs new PI3K inhibitors
Read More
Santaris Pharma advances second cardiometabolic compound into phase I trials
Read More
Health Canada approves new formulation of Emend
Read More
FDA advisory committee recommends approval of Augment bone graft
Read More
Antidepressant Lu-AA21004 enters phase III development in Japan
Read More
Trillium Therapeutics raises funds to advance TTI-1612 into clinical trials
Read More
BioLineRx to reacquire rights to BL-1020 from Cypress Bioscience
Read More
BioFocus and Astellas Pharma sign target discovery agreement for CNS disorders
Read More
University of Florida begins dose-escalating phase I study of OXI-4503 in leukemia
Read More
